Combination therapy of bevacizumab with either S-1 and irinotecan or mFOLFOX6/CapeOX as first-line treatment of metastatic colorectal cancer (TRICOLORE): Exploratory analysis of RAS status and primary tumour location in a randomised, open-label, phase III, non-inferiority trial

European Journal of Cancer ◽

10.1016/j.ejca.2021.06.013 ◽

2021 ◽

Vol 154 ◽

pp. 296-306

Author(s):

Tadamichi Denda ◽

Atsuo Takashima ◽

Makio Gamoh ◽

Ichiro Iwanaga ◽

Yoshito Komatsu ◽

...

Keyword(s):

Colorectal Cancer ◽

Primary Tumour ◽

Phase Iii ◽

Line Treatment ◽

First Line ◽

Open Label ◽

Open Label Phase ◽

Tumour Location ◽

Ras Status ◽

First Line Treatment

Download Full-text

S-1 and irinotecan plus bevacizumab versus mFOLFOX6 or CapeOX plus bevacizumab as first-line treatment in patients with metastatic colorectal cancer (TRICOLORE): a randomized, open-label, phase III, noninferiority trial

Annals of Oncology ◽

10.1093/annonc/mdx816 ◽

2018 ◽

Vol 29 (3) ◽

pp. 624-631 ◽

Cited By ~ 21

Author(s):

Y. Yamada ◽

T. Denda ◽

M. Gamoh ◽

I. Iwanaga ◽

S. Yuki ◽

...

Keyword(s):

Colorectal Cancer ◽

Metastatic Colorectal Cancer ◽

Phase Iii ◽

Line Treatment ◽

First Line ◽

Open Label ◽

Noninferiority Trial ◽

Open Label Phase ◽

First Line Treatment

Download Full-text

Open label phase III study of arfolitixorin vs leucovorin in mFOLFOX-6 for first-line treatment of metastatic colorectal cancer: AGENT

Annals of Oncology ◽

10.1093/annonc/mdz246.141 ◽

2019 ◽

Vol 30 ◽

pp. v249-v250

Author(s):

J. Tabernero ◽

G. Prager ◽

S. Stintzing ◽

H.J. Lenz ◽

H.P. Nygren ◽

...

Keyword(s):

Colorectal Cancer ◽

Metastatic Colorectal Cancer ◽

Phase Iii ◽

Line Treatment ◽

First Line ◽

Open Label ◽

Open Label Phase ◽

Phase Iii Study ◽

Cancer Agent ◽

First Line Treatment

Download Full-text

Randomized, open-label, phase III study of panitumumab (pmab) with FOLFOX4 versus FOLFOX4 alone as first-line treatment (tx) for metastatic colorectal cancer (mCRC): Efficacy by skin toxicity (ST).

Journal of Clinical Oncology ◽

10.1200/jco.2010.28.15_suppl.3528 ◽

2010 ◽

Vol 28 (15_suppl) ◽

pp. 3528-3528 ◽

Cited By ~ 8

Author(s):

J. Douillard ◽

J. Cassidy ◽

J. Jassem ◽

F. Rivera ◽

I. Kocáková ◽

...

Keyword(s):

Colorectal Cancer ◽

Metastatic Colorectal Cancer ◽

Skin Toxicity ◽

Phase Iii ◽

Line Treatment ◽

First Line ◽

Open Label ◽

Open Label Phase ◽

Phase Iii Study ◽

First Line Treatment

Download Full-text

FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial

The Lancet Oncology ◽

10.1016/s1470-2045(14)70330-4 ◽

2014 ◽

Vol 15 (10) ◽

pp. 1065-1075 ◽

Cited By ~ 881

Author(s):

Volker Heinemann ◽

Ludwig Fischer von Weikersthal ◽

Thomas Decker ◽

Alexander Kiani ◽

Ursula Vehling-Kaiser ◽

...

Keyword(s):

Colorectal Cancer ◽

Metastatic Colorectal Cancer ◽

Line Treatment ◽

First Line ◽

Open Label ◽

Phase 3 ◽

Open Label Phase ◽

First Line Treatment

Download Full-text

PCN161 COST-EFFECTIVENESS OF FOLFIRI + CETUXIMAB VS. FOLFIRI + BEVACIZUMAB IN FIRST-LINE TREATMENT OF RAS WILD-TYPE (WT) METASTATIC COLORECTAL CANCER WITH LEFT-SIDED PRIMARY TUMOUR LOCATION IN ITALY: A COUNTRY ADAPTATION BASED ON THE FIRE-3 TRIAL

Value in Health ◽

10.1016/j.jval.2019.09.357 ◽

2019 ◽

Vol 22 ◽

pp. S467

Author(s):

I. van Oostrum ◽

G.M. Bruno ◽

P. Novelli ◽

C. Pescott

Keyword(s):

Colorectal Cancer ◽

Cost Effectiveness ◽

Metastatic Colorectal Cancer ◽

Primary Tumour ◽

Line Treatment ◽

Wild Type ◽

First Line ◽

Tumour Location ◽

First Line Treatment

Download Full-text

LUX-lung 3: A randomized, open-label, phase III study of afatinib vs pemetrexed and cisplatin as first-line treatment for patients with advanced adenocarcinoma of the lung harboring EGFR-activating mutations

Lung Cancer ◽

10.1016/j.lungcan.2012.05.043 ◽

2012 ◽

Vol 77 ◽

pp. S25-S26 ◽

Cited By ~ 18

Author(s):

Martin Schuler ◽

James Chih-Hsin Yang ◽

Nobuyuki Yamamoto ◽

Ken O’Byrne ◽

Vera Hirsh ◽

...

Keyword(s):

Phase Iii ◽

Line Treatment ◽

First Line ◽

Open Label ◽

Activating Mutations ◽

Adenocarcinoma Of The Lung ◽

Open Label Phase ◽

Phase Iii Study ◽

First Line Treatment

Download Full-text

Squire: a Randomized, Multicenter, Open-Label, Phase III Study of Gemcitabine-Cisplatin (Gc) Chemotherapy Plus Necitumumab (Imc-11F8/Ly3012211) Vs Gc Alone in the First-Line Treatment of Patients (Pts) with Stage Iv Squamous Non-Small Cell Lung Cancer (Sq-Nsclc): Update on Key Subgroups

Annals of Oncology ◽

10.1093/annonc/mdu349.11 ◽

2014 ◽

Vol 25 ◽

pp. iv430 ◽

Cited By ~ 1

Author(s):

M.A. Socinski ◽

L. Paz-Ares ◽

A.V. Luft ◽

A. Szczesna ◽

T.E. Ciuleanu ◽

...

Keyword(s):

Stage Iv ◽

Small Cell ◽

Phase Iii ◽

Line Treatment ◽

Small Cell Lung ◽

First Line ◽

Open Label ◽

Open Label Phase ◽

Phase Iii Study ◽

First Line Treatment

Download Full-text

A randomized, multicenter, open-label, phase III study of gemcitabine-cisplatin (GC) chemotherapy plus necitumumab (IMC-11F8/LY3012211) versus GC alone in the first-line treatment of patients (pts) with stage IV squamous non-small cell lung cancer (sq-NSCLC).

Journal of Clinical Oncology ◽

10.1200/jco.2014.32.15_suppl.8008 ◽

2014 ◽

Vol 32 (15_suppl) ◽

pp. 8008-8008 ◽

Cited By ~ 18

Author(s):

Nick Thatcher ◽

Fred R. Hirsch ◽

Aleksandra Szczesna ◽

Tudor-Eliade Ciuleanu ◽

Wojciech Szafranski ◽

...

Keyword(s):

Stage Iv ◽

Small Cell ◽

Phase Iii ◽

Line Treatment ◽

Small Cell Lung ◽

First Line ◽

Open Label ◽

Open Label Phase ◽

Phase Iii Study ◽

First Line Treatment

Download Full-text

A Randomized Open-Label Phase III Trial Evaluating the Addition of Denosumab to Standard First-Line Treatment in Advanced NSCLC: The European Thoracic Oncology Platform (ETOP) and European Organisation for Research and Treatment of Cancer (EORTC) SPLENDOUR Trial

Journal of Thoracic Oncology ◽

10.1016/j.jtho.2020.06.011 ◽

2020 ◽

Vol 15 (10) ◽

pp. 1647-1656 ◽

Cited By ~ 4

Author(s):

Solange Peters ◽

Sarah Danson ◽

Baktiar Hasan ◽

Urania Dafni ◽

Niels Reinmuth ◽

...

Keyword(s):

Advanced Nsclc ◽

Phase Iii ◽

Line Treatment ◽

First Line ◽

Open Label ◽

Phase Iii Trial ◽

European Organisation ◽

Open Label Phase ◽

First Line Treatment

Download Full-text

FOLFOXIRI plus bevacizumab versus FOLFIRI plus bevacizumab as first-line treatment of patients with metastatic colorectal cancer: updated overall survival and molecular subgroup analyses of the open-label, phase 3 TRIBE study

The Lancet Oncology ◽

10.1016/s1470-2045(15)00122-9 ◽

2015 ◽

Vol 16 (13) ◽

pp. 1306-1315 ◽

Cited By ~ 398

Author(s):

Chiara Cremolini ◽

Fotios Loupakis ◽

Carlotta Antoniotti ◽

Cristiana Lupi ◽

Elisa Sensi ◽

...

Keyword(s):

Colorectal Cancer ◽

Overall Survival ◽

Line Treatment ◽

First Line ◽

Open Label ◽

Phase 3 ◽

Molecular Subgroup ◽

Subgroup Analyses ◽

Open Label Phase ◽

First Line Treatment

Download Full-text